428855-17-8

Basic information

• Product Name: 1-[[BIS(PHENYLMETHYL)AMINO]METHYL] CYCLOPROPANOL
• Synonyms: 1-[[BIS(PHENYLMETHYL)AMINO]METHYL] CYCLOPROPANOL;N,N-DIBENZYL-1-HYDROXYL-CYCLOPROPYLMETHANAMINE;1-[(DibenzylaMino)-Methyl]-cyclopropanol hydrochloride;1-((dibenzylaMino)Methyl)cyclopropanol;1-[(dibenzylamino)methyl]cyclopropan-1-ol
• CAS NO: 428855-17-8
• Molecular Formula: C₁₈H₂₁NO
• Molecular Weight: 267.37
• Mol File: 428855-17-8.mol

Chemical Properties

• Boiling Point: 383.8°Cat760mmHg
• Flash Point: 175.9°C
• Appearance: /
• Density: 1.155g/cm³
• Vapor Pressure: 1.41E-06mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: 2-8°C(protect from light)
• PKA: 14.86±0.20(Predicted)
• CAS DataBase Reference: 1-[[BIS(PHENYLMETHYL)AMINO]METHYL] CYCLOPROPANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[[BIS(PHENYLMETHYL)AMINO]METHYL] CYCLOPROPANOL(428855-17-8)
• EPA Substance Registry System: 1-[[BIS(PHENYLMETHYL)AMINO]METHYL] CYCLOPROPANOL(428855-17-8)

Safety Data

• Hazardous Substances Data: 428855-17-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-[[BIS(PHENYLMETHYL)AMINO]METHYL] CYCLOPROPANOL is used as a potential pharmaceutical agent for its possible steroidal or hormone-like properties, which may be beneficial in the development of drugs targeting various medical conditions.
Used in Medicinal Chemistry:
1-[[BIS(PHENYLMETHYL)AMINO]METHYL] CYCLOPROPANOL is used as a compound in medicinal chemistry research for its potential to bind to receptors or enzymes, which could lead to the discovery of new therapeutic agents or treatments for specific diseases.
Note: The specific applications and industries for 1-[[BIS(PHENYLMETHYL)AMINO]METHYL] CYCLOPROPANOL are not explicitly provided in the materials. The uses listed above are inferred based on the compound's structure and potential properties. Further research would be necessary to confirm these applications and identify additional uses.

InChI:InChI=1/C18H21NO/c20-18(11-12-18)15-19(13-16-7-3-1-4-8-16)14-17-9-5-2-6-10-17/h1-10,20H,11-15H2

Upstream product

• 77385-90-1 N,N-dibenzylglycine ethyl ester 
• 925-90-6 ethylmagnesium bromide 
• 103-49-1 dibenzylamine 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 94226-55-8 (dibenzylamino)acetic acid methyl ester 

Downstream Products

• 74592-33-9 1-(aminomethyl)cyclopropan-1-ol 

Relevant articles and documents

ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF

The present invention relates to an FGFR4 inhibitor having a structure represented by formula (I), preparation method therefor, and applications thereof. A series of compounds represented by formula (I) in the present invention have a very-strong inhibiti

NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

Heterocyclic compound

本發明提供一種具有CDK8/19抑制活性之雜環化合物。本發明提供一種如下式代表之化合物(其中各代號均如本文之定義)或其鹽。 The present invention provides a heterocyclic compound possessing CDK8/19 inhibitory activity. The present invention provides a compound represented by the formula wherein each symbol is as defined herein, or a salt thereof.

Intermediate compound of medicine LB80380 and preparing method and application thereof

The invention provides an LB80380 intermediate compound (as shown in formula I in the specification). In the LB80380 intermediate compound, R1, R2, R3 and R4 are chosen from linear chain or branched chain alkyl group, benzyl group which is replaced by one or five R5, or R5CO independently, wherein the R1, the R1, the R3 and the R4 are identical or different; R5 is chosen from hydrogen, C1-C4 alkoxy which is replaced or not replaced, C3-C7 alkenyl alkoxy, or benzyloxy- which is replaced or not replaced. The invention also provides a preparing method and an application of the compound in the formula I. When the compound in formula I is used for preparing a compound (specific chemical formula is in the specification), reaction route raw materials and intermediate materials are low in price and easy to get, cost is low, safety is good, and thus the LB80380 intermediate compound in formula I is applicable to industrial production.

HETEROCYCLIC COMPOUND

The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.

AROMATIC COMPOUND

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

A convenient procedure for preparation of 1-(1-aminoalkyl)-1-cyclopropanols from N-benzyl α-amino acid esters

The reaction of N-benzyl α-amino acid ethyl esters with ethylmagnesium bromide in the presence of a catalytic amount of titanium tetraisopropoxide leads to formation of the corresponding 1-aminoalkyl-1-cyclopropanols in high yields. Hydrogenation of the l